GET DAILY SIGNALSProtalix BioTherapeutics (PLX) Analyst Target of $11 Implies +328% Upside
Key Takeaways
- The $11 central target represents the average of two verified analyst price targets for PLX, ranging from $10 to $12.
- From a recent price near $2.57, hitting $11 would mean upside exceeding 300%, a substantial move even for a small-cap biotech.
- Coverage remains very limited, with just two tracked targets and no Hold or Sell ratings in the current data.
- Positive drivers include Elfabrio sales growth, a favorable European regulatory opinion, and better profitability trends.
- Major risks center on reliance on a single partner, uneven quarterly revenue, and binary outcomes in the pipeline.
- Additional context is available through dedicated pages on Major News, Today's Price Move, Forecast, and Earnings history.
Understanding the Analyst Price Targets
In my view, the two credible targets stand out clearly. H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating and $12 target in September 2026, pointing to Elfabrio momentum and pipeline potential. Another target from S&P Global data sits at $10. That produces a $10-to-$12 range with an arithmetic mean of $11.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This calculated average is not an official consensus, and the thin coverage means it serves more as a directional benchmark than a broad market view.
Current Position and Path to the Target
PLX closed near $2.57 in early November 2026, inside a 52-week range of about $1.65 to $3.19, with a market cap near $207 million. Reaching the $11 target from here would require a gain of roughly 328%. The company has started posting net income and positive free cash flow, with trailing twelve-month revenue around $80 million. A steady shift toward reliable commercial revenue growth appears central to any re-rating.
Elements That Could Support Higher Valuations
- Elfabrio commercial momentum. The Fabry disease treatment, partnered with Chiesi, continues to show accelerating sales.
- European label expansion. The CHMP issued a positive opinion on a 2 mg/kg every-four-weeks regimen, which may improve convenience and market reach.
- Improving profitability. A solid EPS beat occurred in mid-2026, and analysts expect meaningful 2026 revenue growth.
- Pipeline optionality. PRX-115 for gout remains on track for topline data in the second half of 2027.
- Index inclusion. Addition to the S&P Global BMI Index could lift visibility and institutional interest.
Key Risks That Could Limit Upside
- Partner concentration. Commercial results depend heavily on the Chiesi relationship.
- Revenue lumpiness. Milestone payments and ordering patterns can cause quarterly swings.
- Clinical and regulatory risk. Pipeline assets face binary outcomes, with immunogenicity still worth watching.
- Thin coverage and liquidity. The small market cap and limited following can heighten volatility.
- Valuation assumptions. Targets assume sustained profitability and a higher future P/E multiple.
Technical Levels and Market Structure
From a technical standpoint, PLX has traded in a base between roughly $1.65 and $3.19 over the past year. The $3.19 high marks key resistance, while $1.65 serves as major support. Because the $11 target lies well beyond the recent range, technical signals provide limited guidance; any move of that magnitude would need to be driven by fundamental re-rating.
Time Horizon and Items to Monitor
Analyst targets typically reflect a 12-month horizon. For PLX, the most relevant items ahead include quarterly earnings, Elfabrio sales updates, the European dosing decision, and progress on the PRX-115 program. Gross margins, cash levels, and the durability of profitability will also matter.
Using AI Daily Buy/Sell Signals for Ongoing Tracking
I have found Tickeron’s AI Daily Buy/Sell Signals helpful when following names with limited analyst coverage like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It adds a layer of discipline when reviewing positions or spotting trend changes without relying solely on manual review. In my experience, it works well alongside fundamental checks for thinly traded biotechs.
Final Assessment
The $11 central target for Protalix BioTherapeutics (PLX) averages two verified analyst targets between $10 and $12 and points to more than 300% upside from current levels. The constructive case rests on Elfabrio’s trajectory, the recent European regulatory development, improving profitability, and longer-term pipeline potential. The main hurdles remain partner concentration, revenue variability, binary clinical outcomes, and limited institutional attention. With thin coverage and a target far outside the recent range, the figure is best viewed as a best-case scenario rather than a near-term expectation. Monitoring Elfabrio sales, regulatory updates, and PRX-115 data will be the key signposts ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PLX turns positive, indicating new upward trend
PLX saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 76 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 58 cases where PLX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PLX just turned positive on November 10, 2026. Looking at past instances where PLX's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
PLX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day moving average for PLX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 32 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (3.498). P/E Ratio (10.583) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.697) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant therapeutic proteins
Industry Biotechnology